EUVIMEDEUVIMED entdecken
Crossref

Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma

Antonio M Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella, Paolo A Ascierto

European Oncology & Haematology · 2017 · 13 (01) · 1

DOI: 10.17925/eoh.2017.13.01.1a ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Oncology & Haematology, 2017. Verfasst von Antonio M Grimaldi und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v trials, combined dabrafenib and trametinib was associated with significant improvements in outcomes compared with dabrafenib or vemurafenib monotherapy, in patients with BRAF-mutant metastatic melanoma. The combination of vemurafenib and cobimetinib has also been investigated. In the phase III CoBRIM study in patients with unresectable stage III-IV BRAF-mutant melanoma, treatment with vemurafenib and cobimetinib resulted in significantly longer progression-free survival and overall survival (OS) compared with vemurafenib alone. One-year OS was 74.5% in the vemurafenib and cobimetinib group and 63.8% in the vemurafenib group, while 2-year OS rates were 48.3% and 38.0%, respectively. The combination was also well tolerated, with a lower incidence of cutaneous squamous-cell carcinoma and keratoacanthoma compared with monotherapy. Dual inhibition of both MEK and BRAF appears to provide a more potent and durable anti-tumour effect than BRAF monotherapy, helping to prevent acquired resistance as well as decreasing adverse events related to BRAF inhibitor-induced activation of the MAPK-pathway. Combined BRAF and MEK inhibition is the standard of care in patients with advanced BRAF-mutant melanoma.

Zitieren

APA

Grimaldi, A. M., Simeone, E., Festino, L., Vanella, V., & Ascierto, P. A. (2017). Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma. European Oncology & Haematology, 13(01), 1. https://doi.org/10.17925/eoh.2017.13.01.1a

Vancouver

Grimaldi AM, Simeone E, Festino L, Vanella V, Ascierto PA. Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma. European Oncology & Haematology. 2017;13(01):1. doi:10.17925/eoh.2017.13.01.1a

BibTeX
@article{Grimaldi2017,
  author = {Grimaldi, Antonio M and Simeone, Ester and Festino, Lucia and Vanella, Vito and Ascierto, Paolo A},
  title = {Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma},
  journal = {European Oncology & Haematology},
  year = {2017},
  volume = {13},
  number = {01},
  pages = {1},
  doi = {10.17925/eoh.2017.13.01.1a}
}
Kostenlos starten →